COMPARATIVE CLINICAL EFFECTIVENESS OF AZACITIDINE VERSUS DECITABINE FOR THE FRONT LINE TREATMENT OF ELDERLY ACUTE MYELOID LEUKEMIA (AML) PATIENTS

被引：0
|
作者：
Maurillo, L.
Candoni, A.
Spagnoli, A.
Papayannidis, C.
Borlenghi, E.
Lazzarotto, D.
Fianchi, L.
Sciume, M.
Zannier, M. E.
Buccisano, F.
Riva, M.
Breccia, M.
Fanin, R.
Todisco, E.
Lunghi, M.
De Bellis, E.
Fracchiolla, N.
Musto, P.
Venditti, A.
Rossi, G.
机构：
[1] Fdn Policlin Tor Vergata, Dipartimento Oncoematol, Rome, Italy
[2] Univ Roma La Sapienza, Azienda Sanit Univ Integrata, Ematol, Rome, Italy
[3] Asst Spedalicivili, Ist Ematol BL&A Seragnoli, Brescia, Italy
[4] Azienda Sanit Univ Integrata, Ematol, Trieste, Italy
[5] Univ Cattolica Sacro Cuore, Ematol, Milan, Italy
[6] Asst Spedalicivili, Brescia, Italy
[7] Univ Tor Vergata, Dipartimento Biomed & Prevenz, Rome, Italy
[8] Osped Niguarda Ca Granda, Ematol, Milan, Italy
[9] Univ Roma La Sapienza, Ematol, Rome, Italy
[10] Azienda Sanit Univ Integrata, Trieste, Italy
[11] Univ Piemonte Orientale, Div Oncoematol IEO, SCDU Ematol, Vercelli, Italy
[12] Fdn IRCCS Ca Granda Osped Maggiore, UO Oncohematol, Milan, Italy
[13] Univ Tor Vergata, Dipartimento Biomed & Prevenz, IRCCS CROB, Rome, Italy
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P078
引用
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [31] Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
    Choi, Eun-Ji
    Lee, Je-Hwan
    Park, Han-Seung
    Lee, Jung-Hee
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Woo, Ji Min
    Lee, Kyoo-Hyung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 290 - +
  • [32] DECITABINE AS THE FIRST-LINE TREATMENT FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA; A SINGLE CENTER EXPERIENCE IN KOREA
    Lee, J.
    Park, H.
    Cho, H.
    Jang, J.
    Kim, S. J.
    Kim, Y.
    Kim, J. S.
    Cheong, J. W.
    Min, Y. H.
    HAEMATOLOGICA, 2015, 100 : 658 - 658
  • [33] Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia
    Manda, Sudhir
    Anz, Bertrand
    Benton, Christopher
    Broun, E. Randolph
    Yimer, Habte
    Renshaw, John
    Geils, George F.
    Cruz, Jose
    Fanning, Suzanne
    Melear, Jason
    Sharman, Jeff P.
    Kang, Kingston
    Svensson, Anders
    Pai, Madhavi
    Donnellan, William
    BLOOD, 2021, 138
  • [34] Clinical Responses of Glasdegibplus Low Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods
    Westley, Tracy
    Forsythe, Anna
    Bell, Timothy J.
    Cappelleri, Joseph C.
    Tremblay, Gabriel
    Chan, Geoffrey
    BLOOD, 2018, 132
  • [35] Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality
    Talati, Chetasi
    Kuykendall, Andrew
    Al Ali, Najla
    Kim, Jongphil
    Sehovic, Marina
    Zuckerman, Kenneth S.
    Sallman, David A.
    List, Alan F.
    Padron, Eric
    Komrokji, Rami S.
    Djulbegovic, Benjamin
    Extermann, Martine
    Sweet, Kendra
    Lancet, Jeffrey E.
    BLOOD, 2017, 130
  • [36] An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients
    Pollyea, D. A.
    Kohrt, H. E.
    Rajwanshi, R.
    Gallegos, L.
    Berube, C.
    Coutre, S. E.
    Gotlib, J. R.
    Liedtke, M.
    Mitchell, B. S.
    Medeiros, B. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN ELDERLY PATIENTS (≥75 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML) IN THE AZA-AML-001 STUDY
    Seymour, J. F.
    Buckstein, R.
    Santini, V.
    Doehner, H.
    Stone, R. M.
    Minden, M. D.
    Kuo, C. Y.
    Ben-Yehuda, D.
    Bargay, J.
    Songer, S.
    Weaver, J.
    Beach, C. L.
    Dombret, H.
    LEUKEMIA RESEARCH, 2017, 55 : S67 - S68
  • [38] Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.
    Takahashi, Koichi
    Abaza, Yasmin
    Atallah, Ehab L.
    Medeiros, Bruno C.
    Khal, Sam
    Arellano, Martha Lucia
    Patnaik, Mrinal
    Ghalie, Richard
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy
    Acker, Fabian
    Chromik, Joerg
    Tiedjen, Emily
    Wolf, Sebastian
    Vischedyk, Jonas B.
    Makowka, Philipp
    Enssle, Julius C.
    Kouidri, Khouloud
    Sebastian, Martin
    Steffen, Bjoern
    Oellerich, Thomas
    Serve, Hubert
    Neubauer, Andreas
    Schaefer, Jonas A.
    Bittenbring, Joerg T.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024,
  • [40] Synergistic effect of quinacrine in combination with decitabine for the treatment of acute myeloid leukemia cells in vitro: implication for treatment of AML in the elderly
    Wang, Wenge
    Dicker, David T.
    Claxton, David F.
    Wang, Hong-Gang
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2015, 75
12345